Slowed Movement Stopping in Parkinson's Disease and Focal Dystonia is Improved by Standard Treatment.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 12 2019
Historique:
received: 28 06 2019
accepted: 26 11 2019
entrez: 22 12 2019
pubmed: 22 12 2019
medline: 11 11 2020
Statut: epublish

Résumé

Patients with Parkinson's disease and focal dystonia have difficulty in generating and preventing movement. Reaction time (RT) and stop signal reaction time (SSRT) measure the speed to initiate and stop a movement respectively. We developed a portable device to assess RT and SSRT. This incorporated a novel analysis to measure SSRT more efficiently (optimal combination SSRT, ocSSRT). After validation ocSSRT was measured in Parkinson's disease patients without dyskinesia (PD), cervical dystonia (CD) and writer's cramp. We also assessed how ocSSRT responded to L-dopa in PD patients and botulinum toxin injections in CD patients. Participants were instructed to release a button following a green LED flash on the device. On 25% of trials, a red LED flashed 5-195 ms after the green LED; participations were instructed to abort the button release on these trials. ocSSRT and RT were significantly prolonged in patients with Parkinson's disease and focal dystonia (one-way ANOVA p < 0.001). Administration of L-dopa significantly improved ocSSRT and RT in PD patients (p < 0.001). Administration of botulinum toxin significantly improved ocSSRT, but not RT, in CD patients (p < 0.05). ocSSRT is an easily-administered bedside neuro-physiological tool; significantly prolonged ocSSRT is associated with PD and focal dystonia.

Identifiants

pubmed: 31862983
doi: 10.1038/s41598-019-55321-5
pii: 10.1038/s41598-019-55321-5
pmc: PMC6925208
doi:

Substances chimiques

Levodopa 46627O600J
Botulinum Toxins EC 3.4.24.69

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19504

Subventions

Organisme : Medical Research Council
ID : MC_PC_17168
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P012922/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC/PC/17168
Pays : United Kingdom

Références

World J Biol Psychiatry. 2018 Oct;19(7):527-537
pubmed: 28741401
Exp Clin Psychopharmacol. 2009 Dec;17(6):374-83
pubmed: 19968402
J Int Neuropsychol Soc. 2010 Nov;16(6):1064-76
pubmed: 20719043
Psychopharmacology (Berl). 2013 Nov;230(1):89-111
pubmed: 23681165
Dev Psychol. 1999 Jan;35(1):205-13
pubmed: 9923475
Mov Disord. 2011 Jun;26(7):1282-9
pubmed: 21469207
J Neurol Neurosurg Psychiatry. 1996 Aug;61(2):172-5
pubmed: 8708685
Pharmacol Biochem Behav. 2015 Feb;129:19-25
pubmed: 25459105
Trends Neurosci. 2007 Jul;30(7):357-64
pubmed: 17532060
Exp Brain Res. 2004 Sep;158(2):207-12
pubmed: 15112118
J Neurosci. 2011 May 4;31(18):6891-9
pubmed: 21543619
Mov Disord. 2015 Dec;30(14):1912-20
pubmed: 26275050
Psychol Rev. 2014 Jan;121(1):66-95
pubmed: 24490789
Neurorehabil Neural Repair. 2011 Oct;25(8):765-73
pubmed: 21478498
Am J Psychiatry. 2006 Jul;163(7):1282-4
pubmed: 16816237
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Brain. 1997 Mar;120 ( Pt 3):409-16
pubmed: 9126053
Mov Disord. 2008;23 Suppl 2:S451-60
pubmed: 18668618
Biol Psychiatry. 2003 Dec 15;54(12):1345-54
pubmed: 14675798
Ann Neurol. 2008 Dec;64 Suppl 2:S30-46
pubmed: 19127584
J Cogn Neurosci. 2016 May;28(5):710-23
pubmed: 26836515
Nat Neurosci. 2003 Feb;6(2):115-6
pubmed: 12536210
Exp Brain Res. 2011 Sep;213(4):435-45
pubmed: 21796541
Arch Gen Psychiatry. 1983 Jul;40(7):812
pubmed: 6860082
J Neurol. 2018 Sep;265(9):2088-2096
pubmed: 29980853
Mov Disord. 2007 Jan;22(1):41-7
pubmed: 17115387
Hum Brain Mapp. 2012 Jan;33(1):89-104
pubmed: 21365716
J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):539-44
pubmed: 15026491
Int J Neurosci. 2001 Mar;107(1-2):43-61
pubmed: 11328681
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
BMC Neurosci. 2009 Jul 14;10:75
pubmed: 19602259
Mov Disord. 2013 Jun 15;28(7):863-73
pubmed: 23649720

Auteurs

Supriyo Choudhury (S)

Department of Neurology, Institute of Neurosciences Kolkata, Kolkata, India.

Akash Roy (A)

Department of Neurology, Institute of Neurosciences Kolkata, Kolkata, India.
Department of Physiology, University of Calcutta, Kolkata, India.

Banashree Mondal (B)

Department of Neurology, Institute of Neurosciences Kolkata, Kolkata, India.

Ravi Singh (R)

Department of Neurology, Institute of Neurosciences Kolkata, Kolkata, India.

Saptak Halder (S)

Department of Neurology, Institute of Neurosciences Kolkata, Kolkata, India.

Koustav Chatterjee (K)

Department of Neurology, Institute of Neurosciences Kolkata, Kolkata, India.

Mark R Baker (MR)

Department of Neurology, Royal Victoria Infirmary, Queen Victoria Rd, Newcastle upon Tyne, NE1 4LP, United Kingdom.
Department of Clinical Neurophysiology, Royal Victoria Infirmary, Queen Victoria Rd, Newcastle upon Tyne, NE1 4LP, United Kingdom.
Institute of Neuroscience, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom.

Hrishikesh Kumar (H)

Department of Neurology, Institute of Neurosciences Kolkata, Kolkata, India. rishi_medicine@yahoo.com.

Stuart N Baker (SN)

Institute of Neuroscience, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom. stuart.baker@ncl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH